Newborn screening for congenital adrenal hyperplasia in Tokyo, Japan from 1989 to 2013: A retrospective population-based study

BMC Pediatrics

Volumn 15, Issue 1, 2015, Pages

  Tsuji, Atsumi ^a   Konishi, Kaoru ^b   Hasegawa, Satomi ^b   Anazawa, Akira ^b   Onishi, Toshikazu ^a,c   Ono, Makoto ^a   Morio, Tomohiro ^a   Kitagawa, Teruo ^b   Kashimada, Kenichi ^a,b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Tokyo Association of Health Service   (Japan)

^c Kinki Central Hospital of Mutual Association of Public School Teachers   (Japan)

Author keywords

21 hydroxylase deficiency; Congenital adrenal hyperplasia; Newborn screening

Indexed keywords

ADRENAL CORTEX INSUFFICIENCY; ARTICLE; BIRTH WEIGHT; CONGENITAL ADRENAL HYPERPLASIA; CONTROLLED STUDY; DISEASE CLASSIFICATION; FALSE POSITIVE RESULT; FEMALE; GESTATIONAL AGE; HUMAN; INCIDENCE; INFANT; JAPAN; MAJOR CLINICAL STUDY; MALE; NEWBORN SCREENING; NONCLASSICAL FORM; POPULATION RESEARCH; PREDICTIVE VALUE; REFERENCE VALUE; RETROSPECTIVE STUDY; SALT WASTING FORM; SEX DIFFERENCE; SIMPLE VIRILIZING FORM; STEROID 21 MONOOXYGENASE DEFICIENCY; ADRENAL HYPERPLASIA, CONGENITAL; BLOOD; NEWBORN; PROCEDURES;

HYDROXYPROGESTERONE;

17-ALPHA-HYDROXYPROGESTERONE; ADRENAL HYPERPLASIA, CONGENITAL; BIRTH WEIGHT; GESTATIONAL AGE; HUMANS; INCIDENCE; INFANT, NEWBORN; NEONATAL SCREENING; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TOKYO;

EID: 84949871309     PISSN: None     EISSN: 14712431     Source Type: Journal    
DOI: 10.1186/s12887-015-0529-y     Document Type: Article

References (34)

1. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev. 2000;21(3):245-91.
2. White PC. Neonatal screening for congenital adrenal hyperplasia. Nat Rev Endocrinol. 2009;5(9):490-8.
3. Padilla CD, Therrell BL. Newborn screening in the Asia Pacific region. J Inherit Metab Dis. 2007;30(4):490-506.
4. Therrell Jr BL, Berenbaum SA, Manter-Kapanke V, Simmank J, Korman K, Prentice L, et al. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics. 1998;101(4 Pt 1):583-90.
5. Gidlof S, Wedell A, Guthenberg C, von Dobeln U, Nordenstrom A. Nationwide Neonatal Screening for Congenital Adrenal Hyperplasia in Sweden: A 26-Year Longitudinal Prospective Population-Based Study. JAMA Pediatr. 2014;168(6):567-74.
6. Chu SY, Tsai WY, Chen LH, Wei ML, Chien YH, Hwu WL. Neonatal screening for congenital adrenal hyperplasia in Taiwan: a pilot study. J Formos Med Assoc. 2002;101(10):691-4.
7. Padilla CD, Therrell Jr BL, Working Group of the Asia Pacific Society for Human Genetics on Consolidating Newborn Screening Efforts in the Asia Pacific Region. Consolidating newborn screening efforts in the Asia Pacific region: Networking and shared education. J Community Genet. 2012;3(1):35-45.
8. Kaur G, Srivastav J, Jain S, Chawla D, Chavan BS, Atwal R, et al. Preliminary report on neonatal screening for congenital hypothyroidism, congenital adrenal hyperplasia and glucose-6-phosphate dehydrogenase deficiency: a Chandigarh experience. Indian J Pediatr. 2010;77(9):969-73.
9. Nagasaki K, Asami T, Abe Y, Usuda T, Kikuchi T, Uchiyama M. The occurrence of neonatal acute respiratory disorders in 21-hydroxylase deficiency. Endocr J. 2011;58(7):603-6.
10. Morikawa S, Nakamura A, Fujikura K, Fukushi M, Hotsubo T, Miyata J, et al. Results from 28 years of newborn screening for congenital adrenal hyperplasia in sapporo. Clin Pediatr Endocrinol. 2014;23(2): 35-43.
11. Vital, Health and Social Statistics Division, Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour and Welfare (2015): Summary tables of vital statistics: Japan, each prefecture and 21 major cities. e-stat; Portal Site of Official Statistics of Japan. [http://www.e-stat.go.jp/SG1/estat/CsvdlE.do?sinfid=000027231392]
12. Vital, Health and Social Statistics Division, Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour and Welfare (2015): Live Births in Tokyo, 1983-2013. e-stat; Portal Site of Official Statistics of Japan. [http://www.e-stat.go.jp/SG1/chiiki/CommunityProfileTopDispatchAction.do?code=2]
13. Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(9):4133-60.
14. Vital and Health Statistics Division, Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour and Welfare: Live Births Specified Report of Vital Statistics in FY 2010. [http://www.mhlw.go.jp/english/database/db-hw/FY2010/live_births.html]
15. Tajima T, Fujieda K, Nakae J, Mikami A, Cutler Jr GB. Mutations of the CYP21 gene in nonclassical steroid 21-hydroxylase deficiency in Japan. Endocr J. 1998;45(4):493-7.
16. Tajima T, Fujieda K, Nakae J, Toyoura T, Shimozawa K, Kusuda S, et al. Molecular basis of nonclassical steroid 21-hydroxylase deficiency detected by neonatal mass screening in Japan. J Clin Endocrinol Metab. 1997;82(7):2350-6.
17. Kashimada K, Ishii T, Nagasaki K, Ono M, Tajima T, Yokota I, et al. Clinical, biochemical, and genetic features of non-classical 21-hydroxylase deficiency in Japanese children. Endocr J. 2015;62(3):277-82.
18. Suwa S. Nationwide survey of neonatal mass-screening for congenital adrenal hyperplasia in Japan. Screening. 1994;3:141-51.
19. Suwa S, Igarashi Y, Kato K, Kusunoki T, Tanae A, Niimi K, et al. The clinical surveilance report of congenital adrenal hyperplasia-First chapter: Analysis about the prevalence. The Journal of the Japan Pediatric Society. 1981;85(2):204-10 [published in Japanese language].
20. Vital, Health and Social Statistics Division, Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour and Welfare (2015): Deaths by causes (the list of three-character categories), sex and age: Japan, 1995-2013. e-stat; Portal Site of Official Statistics of Japan. [http://www.e-stat.go.jp/SG1/estat/GL32020101.do]
21. Ogawa E, Fujieda K, Tachibana K, Inomata H, Kinoshita E, Kusuda S, et al. Mortality in Patients with Congenital 21-Hydroxylase Deficiency Diagnosed after the Introduction of a Newborn Screening Program in Japan. Clin Pediatr Endocrinol. 2003;12(1):19-23.
22. Coulm B, Coste J, Tardy V, Ecosse E, Roussey M, Morel Y, et al. Efficiency of neonatal screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency in children born in mainland France between 1996 and 2003. Arch Pediatr Adolesc Med. 2012;166(2):113-20.
23. Steigert M, Schoenle EJ, Biason-Lauber A, Torresani T. High reliability of neonatal screening for congenital adrenal hyperplasia in Switzerland. J Clin Endocrinol Metab. 2002;87(9):4106-10.
24. Van der Kamp HJ, Noordam K, Elvers B, Van Baarle M, Otten BJ, Verkerk PH. Newborn screening for congenital adrenal hyperplasia in the Netherlands. Pediatrics. 2001;108(6):1320-4.
25. Balsamo A, Cacciari E, Piazzi S, Cassio A, Bozza D, Pirazzoli P, et al. Congenital adrenal hyperplasia: neonatal mass screening compared with clinical diagnosis only in the Emilia-Romagna region of Italy, 1980-1995. Pediatrics. 1996;98(3 Pt 1):362-7.
26. Saedi S, Dean H, Dent W, Stockl E, Cronin C. Screening for congenital adrenal hyperplasia: the Delfia Screening Test overestimates serum 17-hydroxyprogesterone in preterm infants. Pediatrics. 1996;97(1):100-2.
27. Allen DB, Hoffman GL, Fitzpatrick P, Laessig R, Maby S, Slyper A. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels. J Pediatr. 1997; 130(1):128-33.
28. Nordenstrom A, Wedell A, Hagenfeldt L, Marcus C, Larsson A. Neonatal screening for congenital adrenal hyperplasia: 17-hydroxyprogesterone levels and CYP21 genotypes in preterm infants. Pediatrics. 2001;108(4):E68.
29. Sarafoglou K, Banks K, Gaviglio A, Hietala A, McCann M, Thomas W. Comparison of one-tier and two-tier newborn screening metrics for congenital adrenal hyperplasia. Pediatrics. 2012;130(5):e1261-8.
30. Janzen N, Peter M, Sander S, Steuerwald U, Terhardt M, Holtkamp U, et al. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab. 2007;92(7):2581-9.
31. Lacey JM, Minutti CZ, Magera MJ, Tauscher AL, Casetta B, McCann M, et al. Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry. Clin Chem. 2004;50(3):621-5.
32. Speiser PW. Nonclassic adrenal hyperplasia. Rev Endocr Metab Disord. 2009; 10(1):77-82.
33. Weintrob N, Brautbar C, Pertzelan A, Josefsberg Z, Dickerman Z, Kauschansky A, et al. Genotype-phenotype associations in non-classical steroid 21-hydroxylase deficiency. Eur J Endocrinol. 2000;143(3):397-403.
34. Simard J, Moisan AM, Morel Y. Congenital adrenal hyperplasia due to 3beta-hydroxysteroid dehydrogenase/Delta(5)-Delta(4) isomerase deficiency. Semin Reprod Med. 2002;20(3):255-76.